{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'screening subject is also a patient of the same Investigator/practice or interaction with medical', 'staff of the treatment facility where the relative receives HAE care, who confirms the diagnosis.', 'No historical laboratory documentation on the relative should be collected in the source', 'documents. A SERPING-1 mutation known or likely to be associated with HAE Type I or II', 'assessed during the screening period is acceptable to confirm the diagnosis of HAE.', 'For subjects with a normal C4 at the screening visit, historical SERPING analysis will not be', 'permitted to establish eligibility.', 'For a C1-INH functional level that is between 50% and the LLN (74%), the site may draw', 'another C1-INH functional level sample or, if desired, have SERPING-1 gene mutational', 'analysis performed. A C1-INH functional level < 50% or a SERPING-1 mutation known or', 'likely to be associated with HAE Type 1 or 2 is acceptable to confirm the diagnosis of HAE.', 'Blood for possible SERPING-1 gene sequencing may be drawn at the Screening visit or during', 'the period between screening and baseline but analyzed only if required (normal C4 at screening', 'or a C1-INH functional level between 50% and the LLN [74%]).', '11.2.11. Other Laboratory Assessments', 'Troponin I, Troponin T, NGAL, and CK-MB will be measured in this study at Baseline, at', 'on-treatment visits (except for Weeks 2 and 26) and at follow-up.', 'C3 level will be taken at Baseline and subsequently only if required for study drug-related rash', '(see Section 11.2.14)', 'A C1-INH antigenic level will be measured at Baseline.', '11.2.12. Pharmacokinetics and Pharmacodynamics', 'All plasma samples for determination of BCX7353 will be analyzed using a validated liquid', 'chromatography-mass spectroscopy assay. The analysis of PK samples obtained from subjects', 'randomized to placebo will be limited. The bioanalytical lab performing the analysis may be', 'given the randomization scheme prior to unblinding to avoid analysis of subjects who received', 'placebo.', 'Blood samples for PK and kallikrein inhibition will be drawn on all subjects at baseline and', 'subsequent visits through Week 48 (except Weeks 2 and 26).', 'Actual date and time of sample collection will be recorded in the CRF. Sites will ensure that the', 'time of the previous dose prior to the blood draw is recorded in the diary (may also be captured', 'in the CRF).', 'Instructions for collection, processing, storage, and shipment of PK samples will be provided to', 'the clinical site in a separate document.', '11.2.13.', 'Pharmacogenomic Testing', 'All subjects who are willing to participate and sign a separate informed consent will have a blood', 'sample drawn at Baseline (or any other time point on study if not obtained at Baseline) for', 'possible exploratory pharmacogenomics testing. Testing may be undertaken in one or more', 'locus/loci if desired by the Sponsor to examine whether allelic variations account for efficacy or', '76']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'safety findings. Samples will be sent to a central laboratory for analysis and results will not be', 'returned to sites.', 'Pharmacogenomic samples will be pseudo-anonymous and will be identified by a code number.', \"Neither the subject's name nor initials will be used on any forms or blood samples. Subjects may\", 'withdraw their consent for participation in the optional pharmacogenomic portion of the study', 'after the sample has been collected by notifying the Investigator. If the sample has not yet been', 'analyzed, it will be destroyed. If the sample has been analyzed, the information that has been', 'collected will be retained.', 'Pharmacogenomic samples will be stored for up to 7 years after the last subject completes the', 'study.', 'Possible SERPING genetic analysis is discussed in Section 11.2.10.', '11.2.14. Rash Assessment', 'Because of the potential for a study drug-related rash, all sites are required to have the ability to', 'obtain high resolution photographs and obtain an appropriate skin biopsy.', 'These can be performed by experienced site physicians or a dermatologist on retainer for this', 'study. All subjects should be instructed to call the site for any new skin rash. Photos may be sent', 'by the subject to the Investigator to help determine the need for urgent medical assessment at the', 'site.', 'Subjects should be medically evaluated within 24 to 36 hours of awareness of any diffuse', 'maculopapular rash that could be drug-related. Rashes that resolve within 24 to 36 hours and', 'therefore cannot be medically evaluated will not result in a protocol deviation. In the event the', 'site is notified of a rash by a subject on the weekend, the medical evaluation and Sponsor', 'notification can be performed on the next working day. The site must inform the Sponsor', 'medical monitor via the EOSI form of all BCX7353-related maculopapular rashes', '(Section 12.1.5.1). If the rash is assessed as not maculopapular (eg, urticarial) or not related to', 'BCX7353 (ie, has a clear alternative etiology), then the rash should be reported as an AE not an', 'EOSI, treated per Investigator judgement, and no further special assessment is required.', 'The following assessments must be completed for all subjects with a diffuse maculopapular rash', 'assessed as related to BCX7353 as soon as logistically possible:', 'Full dermatological exam to include the scope of the rash (location), vital signs, and', 'mucosal examination. The notes documenting the examination should include', 'detailed description of the rash; presence or absence of desquamation; presence or', 'absence of blistering and if present, its extent; presence or absence of mucosal', 'involvement and if present, its extent; and any other associated abnormal physical', 'findings.', 'High resolution photographs taken to provide both detail regarding the rash and', 'details regarding the extent of the rash. Cameras must be able to provide clear images', 'taken in close proximity to the skin. The picture should include a ruler (centimeter)', 'for scale. Every attempt to protect subject anonymity should be made.', '77']\n\n###\n\n", "completion": "END"}